CING Logo

Cingulate Inc. (CING) 

NASDAQ
Market Cap
$15.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
600 of 958
Rank in Industry
329 of 549

Largest Insider Buys in Sector

CING Stock Price History Chart

CING Stock Performance

About Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Insider Activity of Cingulate Inc.

Over the last 12 months, insiders at Cingulate Inc. have bought $0 and sold $841 worth of Cingulate Inc. stock.

On average, over the past 5 years, insiders at Cingulate Inc. have bought $687,630 and sold $11,525 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $3,349 was made by Callahan Jennifer L. (Corporate Controller) on 2023‑09‑15.

List of Insider Buy and Sell Transactions, Cingulate Inc.

2024-08-15SaleEVP and COO
202
0.0346%
$4.17$8410.00%
2023-09-15PurchaseCorporate Controller
5,000
0.031%
$0.67$3,349-91.95%
2023-08-11Purchasedirector
1.82M
16.1208%
$0.55$1M-88.68%
2023-05-15PurchaseCorporate Controller
2,000
0.0184%
$1.01$2,020-61.39%
2023-05-12PurchaseCorporate Controller
4,000
0.0374%
$1.08$4,320-62.62%
2022-12-16PurchaseChief Executive Officer
10,000
0.0879%
$1.02$10,166-11.54%
2022-12-14PurchaseCorporate Controller
7,548
0.0728%
$0.99$7,468+0.16%
2022-12-14PurchaseChief Executive Officer
13,267
0.1305%
$1.01$13,400+0.16%
2022-12-13Purchasedirector
28,934
0.2505%
$0.98$28,422-9.36%
2022-12-13PurchaseChief Executive Officer
1,733
0.0154%
$1.01$1,750-9.36%
2022-11-29PurchaseCorporate Controller
1,530
0.0144%
$0.98$1,499+0.64%
2022-11-28PurchaseCorporate Controller
3,487
0.0304%
$0.98$3,417-7.00%
2022-11-23PurchaseEVP and COO
1,111
0.0098%
$0.90$1,000+2.74%
2022-11-23PurchaseEVP, GC and Secretary
3,575
0.0295%
$0.84$3,003+2.74%
2022-11-22Purchasedirector
85,000
0.766%
$0.88$74,851+6.90%
2022-09-08PurchaseCorporate Controller
3,500
0.0312%
$1.50$5,250-33.89%
2022-09-06Purchase
74,500
0.6459%
$1.52$113,225-36.13%
2022-09-01PurchaseEVP and COO
636
0.0057%
$1.57$999-36.13%
2022-06-01PurchaseEVP and COO
200
0.0018%
$1.18$236-6.90%
2022-05-17PurchaseEVP and COO
200
0.0017%
$1.21$242-12.19%

Insider Historical Profitability

<0.0001%
Myers LaurieEVP and COO
0
0%
$4.8651
Werth Peter J.director
2798320
87.1145%
$4.8640<0.0001%
GIVENS GREGG WMdirector
154318
4.8041%
$4.8620
Callahan Jennifer L.Corporate Controller
45508
1.4167%
$4.8680<0.0001%
Schaffer Shane J.Chief Executive Officer
41500
1.2919%
$4.8630

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.